211 related articles for article (PubMed ID: 19856228)
21. Retroperitoneal malignant peripheral nerve sheath tumor: evaluation with serial FDG-PET.
Chander S; Westphal SM; Zak IT; Bloom DA; Zingas AP; Joyrich RN; Littrup PJ; Taub JW; Getzen TM
Clin Nucl Med; 2004 Jul; 29(7):415-8. PubMed ID: 15192465
[TBL] [Abstract][Full Text] [Related]
22. Imaging biomarkers for malignant peripheral nerve sheath tumors in neurofibromatosis type 1.
Ahlawat S; Blakeley JO; Rodriguez FJ; Fayad LM
Neurology; 2019 Sep; 93(11):e1076-e1084. PubMed ID: 31395668
[TBL] [Abstract][Full Text] [Related]
23. Malignant Peripheral Nerve Sheath Tumor With Bilateral Adrenal Metastases: Role of 18F-FDG PET/CT in Response Assessment to Tyrosine Kinase Inhibitor and Liposomal Doxorubicin.
Tripathy S; Passah A; Singhal A; Prashanth A; Kumar R
Clin Nucl Med; 2019 Jun; 44(6):494-495. PubMed ID: 30889004
[TBL] [Abstract][Full Text] [Related]
24. Anatomic and metabolic evaluation of peripheral nerve sheath tumors in patients with neurofibromatosis 1 using whole-body MRI and (18)F-FDG PET fusion.
Urban T; Lim R; Merker VL; Muzikansky A; Harris GJ; Kassarjian A; Bredella MA; Plotkin SR
Clin Nucl Med; 2014 May; 39(5):e301-7. PubMed ID: 24152623
[TBL] [Abstract][Full Text] [Related]
25. Direct comparison of the diagnostic accuracy of 2-[
Ko WS; Kim SJ
Clin Radiol; 2024 Feb; 79(2):142-149. PubMed ID: 37968227
[TBL] [Abstract][Full Text] [Related]
26. Association between benign and malignant peripheral nerve sheath tumors in NF1.
Tucker T; Wolkenstein P; Revuz J; Zeller J; Friedman JM
Neurology; 2005 Jul; 65(2):205-11. PubMed ID: 16043787
[TBL] [Abstract][Full Text] [Related]
27. 18F-FDG PET/CT Helps Differentiate Peripheral Nerve Myeloid Sarcoma From a Presumed Benign Nerve Sheath Tumor.
Das JP; Riedl CC; Ulaner GA
Clin Nucl Med; 2020 Dec; 45(12):989-991. PubMed ID: 32956122
[TBL] [Abstract][Full Text] [Related]
28. Malignant Peripheral Nerve Sheath Tumor Arising From Transplanted Kidney Assessed by 18F-FDG PET/CT.
Feng H; Tu N; Bu L
Clin Nucl Med; 2020 Nov; 45(11):905-907. PubMed ID: 32969901
[TBL] [Abstract][Full Text] [Related]
29. 18F-fluorodeoxyglucose positron emission tomography/computed tomography in a case of malignant peripheral nerve sheath tumor: An unusual presentation.
D'souza MM; Jaimini A; Kumar Dhali T; D'souza P; Saw S; Sharma R; Mondal A
Indian J Nucl Med; 2013 Jul; 28(3):168-70. PubMed ID: 24250026
[TBL] [Abstract][Full Text] [Related]
30. Comprehensive anatomical and functional imaging in patients with type I neurofibromatosis using simultaneous FDG-PET/MRI.
Reinert CP; Schuhmann MU; Bender B; Gugel I; la Fougère C; Schäfer J; Gatidis S
Eur J Nucl Med Mol Imaging; 2019 Mar; 46(3):776-787. PubMed ID: 30535768
[TBL] [Abstract][Full Text] [Related]
31. The Role of [
Tovmassian D; Abdul Razak M; London K
Int J Surg Oncol; 2016; 2016():6162182. PubMed ID: 28058117
[No Abstract] [Full Text] [Related]
32. The value of 18F-FDG PET/CT in patient with neurofibromatosis type 1: A case report and literature review.
Ren J; Yang G; Zhou J; Fu Z
Medicine (Baltimore); 2018 May; 97(20):e10648. PubMed ID: 29768331
[TBL] [Abstract][Full Text] [Related]
33. Value of PET in the assessment of patients with neurofibromatosis type 1.
Bredella MA; Torriani M; Hornicek F; Ouellette HA; Plamer WE; Williams Z; Fischman AJ; Plotkin SR
AJR Am J Roentgenol; 2007 Oct; 189(4):928-35. PubMed ID: 17885067
[TBL] [Abstract][Full Text] [Related]
34. CT, MRI, and
Kim HY; Hwang JY; Kim HJ; Kim YK; Cha J; Park GM; Kim ST
Acta Radiol; 2017 Oct; 58(10):1222-1230. PubMed ID: 28068826
[TBL] [Abstract][Full Text] [Related]
35. Schwannoma in neurofibromatosis type 1: a pitfall for detecting malignancy by metabolic imaging.
Ahlawat S; Blakeley J; Montgomery E; Subramaniam RM; Belzberg A; Fayad LM
Skeletal Radiol; 2013 Sep; 42(9):1317-22. PubMed ID: 23649401
[TBL] [Abstract][Full Text] [Related]
36. Imaging of non-neurogenic peripheral nerve malignancy-a case series and systematic review.
Luna R; Fayad LM; Rodriguez FJ; Ahlawat S
Skeletal Radiol; 2021 Jan; 50(1):201-215. PubMed ID: 32699955
[TBL] [Abstract][Full Text] [Related]
37. A Bayesian approach for diagnostic accuracy of malignant peripheral nerve sheath tumors: a systematic review and meta-analysis.
Martin E; Geitenbeek RTJ; Coert JH; Hanff DF; Graven LH; Grünhagen DJ; Verhoef C; Taal W
Neuro Oncol; 2021 Apr; 23(4):557-571. PubMed ID: 33326583
[TBL] [Abstract][Full Text] [Related]
38. Nerve Sheath Tumors in Neurofibromatosis Type 1: Assessment of Whole-Body Metabolic Tumor Burden Using F-18-FDG PET/CT.
Salamon J; Papp L; Tóth Z; Laqmani A; Apostolova I; Adam G; Mautner VF; Derlin T
PLoS One; 2015; 10(12):e0143305. PubMed ID: 26625155
[TBL] [Abstract][Full Text] [Related]
39. Limitations and benefits of FDG-PET/CT in NF1 patients with nerve sheath tumors: A cross-sectional/longitudinal study.
Nishida Y; Ikuta K; Ito S; Urakawa H; Sakai T; Koike H; Ito K; Imagama S
Cancer Sci; 2021 Mar; 112(3):1114-1122. PubMed ID: 33415792
[TBL] [Abstract][Full Text] [Related]
40. A-Z of malignant peripheral nerve sheath tumors.
Kamran SC; Shinagare AB; Howard SA; Hornick JL; Ramaiya NH
Cancer Imaging; 2012 Oct; 12(3):475-83. PubMed ID: 23108260
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
